G

Genmab A/S ADS
D

GMAB

20.660
USD
0.19
(0.93%)
Market Closed
Volume
39,947
EPS
9
Div Yield
-
P/E
20
Market Cap
13,121,914,305
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    ILMN
    -7.180
    (-5.05%)
    135.110 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: Genmab A/S ADS

Sector: Healthcare
Industry: Biotechnology
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.